Cantor Fitzgerald Reiterates a Buy Rating on Ultragenyx Pharmaceutical (RARE)

Group 1 - Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is considered a strong buy stock by Wall Street, with a Buy rating and a price target of $105.00 set by Cantor Fitzgerald [1] - The company reported total revenue of $166 million for fiscal Q2 2025, with Crysvita generating $120 million and Dojolvi contributing $23 million [2] - Ultragenyx reaffirmed its revenue guidance for 2025, expecting total revenue in the range of $640 million to $670 million [2] Group 2 - Ultragenyx develops, acquires, and commercializes products for genetic diseases, with a portfolio that includes Crysvita, Mepsevii, Dojolvi, and Evkeeza [3] - In 2024, the company expanded its business through four products across five indications globally [3]